Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Share-based Compensation (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Share-based Compensation data on record, last reported at $2.1 million in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 35.84% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $10.2 million, down 32.71%, while the annual FY2024 figure was $12.4 million, 54.75% down from the prior year.
  • Share-based Compensation reached $2.1 million in Q3 2025 per SGMO's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.5 million in Q2 2021 and bottomed at $2.1 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $5.9 million, with a median of $6.8 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 40.2% in 2021, then crashed 67.15% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $8.1 million in 2021, then increased by 2.13% to $8.2 million in 2022, then fell by 25.96% to $6.1 million in 2023, then tumbled by 46.24% to $3.3 million in 2024, then plummeted by 35.21% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.1 million in Q3 2025, $2.2 million in Q2 2025, and $2.6 million in Q1 2025.